On the 29th, Sino Biopharm (HK.1177) released its 2023 Environmental, Social, and Governance (ESG) Report. This is the third consecutive ESG report released by Sino Biopharm since it began systematically promoting its ESG work. This year, the Group's ESG governance system remained effective, the CARE ESG strategy was fully implemented, and the three-year plan (2022-2024) was steadily carried out, with phased progress achieved in key areas such as "carbon neutrality planning", "hazardous waste reduction planning", "responsible supply chain construction", and "human development planning".

The Group's practices and achievements in the ESG field have received attention, response, and recognition from stakeholders across all sectors. During the reporting period, the Group's MSCI ESG rating was upgraded to A, and its CSA score ranked in the top 9% of global peers for two consecutive years. It also won multiple major international ESG awards.